Stockscreener 앱 받기
1.43
25.44%
0.29
시간 외 거래:
1.35
-0.08
-5.59%
전일 마감가:
$1.14
열려 있는:
$1.25
하루 거래량:
20.01M
Relative Volume:
1.43
시가총액:
$6.72M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.5652
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
+156.23%
1개월 성능:
+32.41%
6개월 성능:
-7.14%
1년 성능:
-25.52%
1일 변동 폭
$1.24
$1.57
1주일 범위
$0.4907
$2.08
52주 변동 폭
$0.284
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.43 | 6.72M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.04 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.14 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
605.52 | 36.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
280.96 | 36.37B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.47 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | D. Boral Capital | Buy |
| 2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
| 2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Plus Therapeutics Introduces REYOBIQ - citybiz
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView
Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com newswire
Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey
10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey
Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com
FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa
Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks
FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India
Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire
Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan
Plus Therapeutics Sets Earnings Date: CNS Cancer Drug Developer to Report Q4 Results - StockTitan
Plus Therapeutics, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq
Plus Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital - Defense World
Plus Therapeutics stock gains on Boral Capital Buy rating By Investing.com - Investing.com South Africa
Plus Therapeutics stock gains on Boral Capital Buy rating - Investing.com India
D. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy Recommendation - Nasdaq
Plus Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Plus Therapeutics regains compliance with Nasdaq minimum stockholders’ equity requirement - MSN
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph
Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan
Plus Therapeutics Regains Nasdaq Compliance - Nasdaq
Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia
Plus Therapeutics regains Nasdaq compliance - Investing.com India
SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow
Plus Therapeutics regains Nasdaq compliance status - Investing.com India
Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement - GlobeNewswire
Plus Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Nasdaq
Plus Therapeutics Secures Future on Nasdaq After Meeting Equity Requirements - StockTitan
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - MSN
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Insider Monkey
Plus Therapeutics Announces Peer-Reviewed Publication in - GlobeNewswire
Plus Therapeutics Continues Rally On FridayHere's Why - Benzinga
Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise - Marketscreener.com
Pre-Hour Momentum Drives Plus Therapeutics (PSTV) Stock Higher On FDA Designation - Stocks Telegraph
FDA ODD given to Plus Therapeutics’ injectable radiotherapy - Yahoo Finance
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma - Yahoo Finance
RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial - Nature.com
Plus Therapeutics’ $15 Million Private Placement - Global Legal Chronicle
Pharma Stock Plus Therapeutics, Inc. (Nasdaq: $PSTV) Makes NASDAQ Top Gainer List on FDA News - Investorideas.com newswire
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge - Marketscreener.com
Plus Therapeutics stock rises on FDA Orphan tag (PSTV:NASDAQ) - Seeking Alpha
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment By Investing.com - Investing.com South Africa
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment - Investing.com
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda - Marketscreener.com
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.03%
자본화:
|
볼륨(24시간):